Seeking Alpha

Adam Feuerstien tips off that a response from a FDA spokesperson on MAP Pharmaceuticals' (MAPP...

Adam Feuerstien tips off that a response from a FDA spokesperson on MAP Pharmaceuticals' (MAPP +6.9%) Levadex "sounds like a rejection" for the drug that aims to treat migraine headaches. Shares of MAPP are up 30% YTD, helped in part by speculation that an approval on the drug could help the company ring up sales of over $100M in 2013.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs